ClinicalTrials.gg
CompletedNCT03293498Updated Dec 21, 2022Results posted

Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)

A Phase 1/2 interventional study of NanoFlu and Fluzone HD - Day 0 in Influenza, sponsored by Novavax. Completed at 3 sites in United States. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-21.

Sponsored by Novavax · Phase 1/2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Influenza, Human by Novavax — none open to participants now, none under way, none of them phase 3. Influenza, Human · Novavax.

Enrollment
12th of 18
330 · median 367
Started
2017
the only one that year
Phase 1/2
3 of 18
none open now
Registered
12th of 18
by date

Among the 18 studies in Influenza, Human by Novavax, this one is the 12th largest by enrollment, is the only one that started in 2017, is one of 3 in phase 1/2, and was the 12th registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

None of the 18 studies in Influenza, Human by Novavax is open now. The open studies under Influenza, Human, anywhere →

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies in Influenza, Human by Novavax as a file.
02

Study summary

This was a Phase 1/2, randomized, observer-blinded, active-controlled trial to assess the Safety and Tolerability of a Recombinant Trivalent Nanoparticle Influenza Vaccine (Tri-NIV) with Matrix M1™ Adjuvant in Healthy Older Adults ≥ 60 Years of Age

Read the detailed description

Study tNIV-E-101 a randomized, observer-blinded, active-controlled trial designed to evaluate the safety and immunogenicity of Novavax's insect cell-derived, egg-free, influenza vaccine (Tri-NIV) based on recombinant HA nanoparticle antigens, representing the 3 major influenza types/subtypes recommended for inclusion in the 2017 - 2018 seasonal influenza vaccine by the World Health Organization (WHO) and the Center for Biologics Evaluation and Research (CBER) Approximately 330 eligible subjects were enrolled and randomized into 1 of 3 treatment groups Each group consisted of approximately 110 subjects total, stratified by age, gender, and history of receipt of the 2016 - 17 influenza vaccine. On Day 0, subjects in Groups A and B were administered an IM injection of NanoFlu at one of two dose levels; subjects in Group C received the preconfigured comparator (Fluzone HD) at the manufacturer's recommended dose and volume. On Day 21, all Group A and B subjects were administered a rescue injection with a licensed seasonal influenza vaccine. In contrast, all Group C subjects were administered an injection with a sterile saline placebo to maintain the trial blind. Trial follow-up for each subject spanned approximately 1 year from Day 0.

03

Conditions studied

  • Influenza

Browse trials for

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy older adults, male or female,
  2. Willing and able to give prior to trial enrollment, and
  3. Able to attend trial visits, comply with trial requirements, and provide reliable and complete reports of adverse events.

Exclusion criteria

Exclusion Criteria:

  1. Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care.

    • Asymptomatic chronic conditions or findings (eg, mild hypertension, dyslipidemia) that are not associated with evidence of end-organ damage are not exclusionary provided that they are being appropriately managed and are clinically stable (ie, unlikely to result in symptomatic illness within the time-course of this trial) in the opinion of the investigator.
    • Acute or chronic illnesses or conditions which may be reasonably predicted to become symptomatic if treatment were withdrawn or interrupted are exclusionary, even if stable.
    • Acute or chronic illnesses reasonably expected to be associated with increased risks in the event of influenza infection (eg, cardio-pulmonary diseases, diabetes mellitus, renal or hepatic dysfunction, hemoglobinopathies) are exclusionary, even if stable.
    • Note that illnesses or conditions may be exclusionary, even if otherwise stable, due to therapies used to treat them (see exclusion criteria 2, 5, 8, 9).
  2. Participation in research involving product (drug / biologic / device) within 45 days before planned date of first injection.
  3. History of a serious reaction to prior influenza vaccination, or known allergy to constituents of influenza vaccines - including egg proteins - or polysorbate 80.
  4. History of Guillain-Barré Syndrome (GBS) within 6 weeks following a previous influenza vaccine.
  5. Receipt of any vaccine in the 4 weeks preceding the trial vaccination and any influenza vaccine within 6 months preceding the trial vaccination.
  6. Any known or suspected illness, congenital or acquired, based on medical history and/or physical examination.
  7. Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the trial vaccine. An immunosuppressant dose of will be defined as a systemic dose ≥ 10 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted.
  8. Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the trial vaccine or during the trial.
  9. Acute disease at the time of enrollment (defined as the presence of a moderate or severe illness with or without fever, or an oral temperature > 38.0°C, on the planned day of vaccine administration).
  10. Any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled or could interfere with evaluation of the vaccine or interpretation of trial results (including neurologic or psychiatric conditions deemed likely to impair the quality of safety reporting).
  11. Known disturbance of coagulation.
  12. Suspicion or recent history (within one year of planned vaccination) of alcohol or other substance abuse.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
330 participants (actual)

Study arms

  • Experimental
    Group A

    Low dose NanoFlu - Day 0; Fluzone HD - Day 21

    Biological: NanoFlu · Biological: Fluzone HD - Day 21

  • Experimental
    Group B

    High dose NanoFlu - Day 0; Fluzone HD - Day 21

    Biological: NanoFlu · Biological: Fluzone HD - Day 21

  • Active comparator
    Group C

    Fluzone HD - Day 0; Saline - Day 21

    Biological: Fluzone HD - Day 0 · Other: Saline - Day 21

Interventions

  • BiologicalNanoFlu

    Vaccine

  • BiologicalFluzone HD - Day 0

    Vaccine

  • BiologicalFluzone HD - Day 21

    Vaccine

  • OtherSaline - Day 21

    Placebo

06

What researchers measure

Primary outcomes

  1. Number of Participants With All Adverse Events (AEs), Medically Attended Adverse Events (MAAEs), Serious Adverse Events (SAEs), and Significant New Medical Conditions (SNMCs).

    Number of participants that reported all adverse event (AE) profile (including adverse changes in clinical laboratory parameters) ; medically-attended adverse event (MAE), serious adverse event (SAE), and significant new medical condition (SNMC) post dosing.

    Time frame: Day 0 - Day 21 post dosing

  2. Number of Participants With Solicited Local and Systemic AEs

    Number of participants with solicited local and systemic adverse events over the 7 days post-injection

    Time frame: Day 0 - Day 6 post-dosing

  3. Geometric Mean Titers (GMT) Specific for the Hemagglutinin (HA) Receptor Binding Domains of Each of the Virus Strains Included in the NanoFlu as Measured by the Hemagglutination Inhibition (HAI) Assay.

    The immunogenicity of Tri-NIV at 2 different doses, and the licensed comparator Fluzone HD (Sanofi Pasteur), in healthy older adults ≥ 60 years of age, based on hemagglutination inhibition (HAI) responses to vaccine-homologous influenza A and B strains, as recommended for the 2017 - 18 Northern hemisphere vaccine, at Day 21 post-dosing expressed as GMTs.

    Time frame: Day 0 - Day 21 post dosing

  4. Geometric Mean Ratio (GMR) Specific for the HA Receptor Binding Domains of Each of the Virus Strains Included in the NanoFlu as Measured by the HAI Assay.

    The immunogenicity of Tri-NIV at 2 different doses, and the licensed comparator Fluzone HD (Sanofi Pasteur), in healthy older adults ≥ 60 years of age, based on hemagglutination inhibition (HAI) responses to vaccine-homologous influenza A and B strains, as recommended for the 2017 - 18 Northern hemisphere vaccine, at Day 21 post-dosing expressed as GMR.

    Time frame: Day 0 - Day 21 post dosing

  5. Seroconversion Rate (SCR) Specific for the HA Receptor Binding Domains of Each of the Virus Strains Included in the NanoFlu as Measured by the HAI Assay.

    The immunogenicity of Tri-NIV at 2 different doses, and the licensed comparator Fluzone HD (Sanofi Pasteur), in healthy older adults ≥ 60 years of age, based on hemagglutination inhibition (HAI) responses to vaccine-homologous influenza A and B strains, as recommended for the 2017 - 18 Northern hemisphere vaccine, at Day 21 post-dosing expressed as SCRs.

    Time frame: Day 0 - Day 21 post dosing

  6. Number of Participants With Seroprotection Specific for the HA Receptor Binding Domains of Each of the Virus Strains Included in the NanoFlu as Measured by the HAI Assay.

    The immunogenicity of Tri-NIV at 2 different doses, and the licensed comparator Fluzone HD (Sanofi Pasteur), in healthy older adults ≥ 60 years of age, based on hemagglutination inhibition (HAI) responses to vaccine-homologous influenza A and B strains, as recommended for the 2017 - 18 Northern hemisphere vaccine, at Day 21 post-dosing expressed as SPRs. Seroprotection rate (SPR) - defined as the number of subjects with an HAI titer ≥ 1:40.

    Time frame: Day 0 - Day 21 post dosing

Secondary outcomes

  1. Geometric Mean Titers (GMT) Specific for the HA Receptor Binding Domains of at Least 2 Historic A Virus Strains (One H1N1 and One H3N2) as Measured by the HAI Assay

    The immunogenicity of Tri-NIV at 2 different doses and the licensed comparator Fluzone HD (Sanofi Pasteur) based on hemagglutination inhibition (HAI) responses to at least 2 historic and/or drifted A virus strains (one H1N1 and one H3N2) expressed as GMTs.

    Time frame: Day 0 - Day 21

  2. Geometric Mean Ratio (GMR) Specific for the HA Receptor Binding Domains of at Least 2 Historic A Virus Strains (One H1N1 and One H3N2) as Measured by the HAI Assay

    The immunogenicity of Tri-NIV at 2 different doses and the licensed comparator Fluzone HD (Sanofi Pasteur) based on hemagglutination inhibition (HAI) responses to at least 2 historic and/or drifted A virus strains (one H1N1 and one H3N2) expressed as GMRs.

    Time frame: Day 0 - Day 21

  3. Seroconversion Rate (SCR) Specific for the HA Receptor Binding Domains of at Least 2 Historic A Virus Strains (One H1N1 and One H3N2) as Measured by the HAI Assay

    The immunogenicity of Tri-NIV at 2 different doses and the licensed comparator Fluzone HD (Sanofi Pasteur) based on hemagglutination inhibition (HAI) responses to at least 2 historic and/or drifted A virus strains (one H1N1 and one H3N2) expressed as SCRs.

    Time frame: Day 0 - Day 21

  4. Number of Participants With Seroprotection Specific for the HA Receptor Binding Domains of at Least 2 Historic A Virus Strains (One H1N1 and One H3N2) as Measured by the HAI Assay

    The immunogenicity of Tri-NIV at 2 different doses and the licensed comparator Fluzone HD (Sanofi Pasteur) based on hemagglutination inhibition (HAI) responses to at least 2 historic and/or drifted A virus strains (one H1N1 and one H3N2) expressed as SPRs. Seroprotection rate (SPR) - defined as the percentage of subjects with an HAI titer ≥ 1:40.

    Time frame: Day 0 - Day 21

  5. Geometric Mean Titers (GMT) for Neutralizing Antibody Titers Specific for the Virus Strains Included in NanoFlu and the Fluzone HD Comparator, as Well as Selected Historical A Strains, as Measured by a Microneutralization Assay.

    The immunogenicity of Tri-NIV at 2 different doses, and the licensed comparator Fluzone HD (Sanofi Pasteur), based on microneutralization (MN) responses to vaccine-homologous and historic and/or drifted influenza A strains, and the vaccine-homologous B/Victoria lineage strain, at Day 21 post-dosing expressed as GMTs.

    Time frame: Day 0 - Day 21 post dosing

  6. Geometric Mean Ratio (GMR) for Neutralizing Antibody Titers Specific for the Virus Strains Included in NanoFlu and the Fluzone HD Comparator, as Well as Selected Historical A Strains, as Measured by a Microneutralization Assay.

    The immunogenicity of Tri-NIV at 2 different doses, and the licensed comparator Fluzone HD (Sanofi Pasteur), based on microneutralization (MN) responses to vaccine-homologous and historic and/or drifted influenza A strains, and the vaccine-homologous B/Victoria lineage strain, at Day 21 post-dosing expressed as GMRs.

    Time frame: Day 0 - Day 21

  7. Seroconversion Rate (SCR) for Neutralizing Antibody Titers Specific for the Virus Strains Included in NanoFlu and the Fluzone HD Comparator, as Well as Selected Historical A Strains, as Measured by a Microneutralization Assay.

    The immunogenicity of Tri-NIV at 2 different doses, and the licensed comparator Fluzone HD (Sanofi Pasteur), based on microneutralization (MN) responses to vaccine-homologous and historic and/or drifted influenza A strains, and the vaccine-homologous B/Victoria lineage strain, at Day 21 post-dosing expressed as SPRs.

    Time frame: Day 0 - Day 21

07

Results

Posted Dec 21, 2022

Participant flow

Participants took part in a study conducted at 3 different clinical sites from September 18, 2017 to October 29, 2018.

Participant flow — Overall Study
MilestoneGroup A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21.
Started109111110
Completed109111110
Not completed000

Outcome measures

PrimaryNumber of Participants With All Adverse Events (AEs), Medically Attended Adverse Events (MAAEs), Serious Adverse Events (SAEs), and Significant New Medical Conditions (SNMCs).

Number of participants that reported all adverse event (AE) profile (including adverse changes in clinical laboratory parameters) ; medically-attended adverse event (MAE), serious adverse event (SAE), and significant new medical condition (SNMC) post dosing.

Time frame:
Day 0 - Day 21 post dosing
Reported as:
Number · participants
Number of Participants With All Adverse Events (AEs), Medically Attended Adverse Events (MAAEs), Serious Adverse Events (SAEs), and Significant New Medical Conditions (SNMCs).
participantsGroup A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21.
MAE's962
SAE's010
SNMC's010
All AEs (21 days post-injection)405251
PrimaryNumber of Participants With Solicited Local and Systemic AEs

Number of participants with solicited local and systemic adverse events over the 7 days post-injection

Time frame:
Day 0 - Day 6 post-dosing
Reported as:
Number · participants
Number of Participants With Solicited Local and Systemic AEs
participantsGroup A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21.
Solicited Local AE's (Day 0 to Day 6)152630
Solicited Systemic AE's (Day 0 to Day 6)232420
PrimaryGeometric Mean Titers (GMT) Specific for the Hemagglutinin (HA) Receptor Binding Domains of Each of the Virus Strains Included in the NanoFlu as Measured by the Hemagglutination Inhibition (HAI) Assay.

The immunogenicity of Tri-NIV at 2 different doses, and the licensed comparator Fluzone HD (Sanofi Pasteur), in healthy older adults ≥ 60 years of age, based on hemagglutination inhibition (HAI) responses to vaccine-homologous influenza A and B strains, as recommended for the 2017 - 18 Northern hemisphere vaccine, at Day 21 post-dosing expressed as GMTs.

Time frame:
Day 0 - Day 21 post dosing
Reported as:
Geometric mean · titers
Geometric Mean Titers (GMT) Specific for the Hemagglutinin (HA) Receptor Binding Domains of Each of the Virus Strains Included in the NanoFlu as Measured by the Hemagglutination Inhibition (HAI) Assay.
titersGroup A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21.
Day 0 (A/Michigan/45/2015 (H1N1))39 (31 to 48)34 (27 to 42)31 (25 to 38)
Day 21 (A/Michigan/45/2015 (H1N1))95 (75 to 121)130 (102 to 166)139.1 (112 to 174)
Day 0 (A/HongKong/4801/2014 (H3N2) )26 (21 to 33)21 (17 to 27)26 (21 to 33)
Day 21 (A/HongKong/4801/2014 (H3N2) )62 (48 to 79)75 (59 to 94)94 (74 to 119)
Day 0 (B/Brisbane/60/2008 (Victoria Lineage))19 (15 to 23)18 (15 to 22)15 (12 to 17)
Day 21 (B/Brisbane/60/2008 (Victoria Lineage))24 (20 to 30)29 (24 to 35)37 (31 to 46)
Day 0 (A/California/07/2009 (H1N1))65 (53 to 80)59 (48 to 73)52 (42 to 64)
Day 21 (A/California/07/2009 (H1N1) )143 (116 to 176)194 (156 to 242)206 (169 to 222)
Day 0 (A/Texas/50/2012 (H3N2) )197 (155 to 251)160 (123 to 207)196 (151 to 253)
Day 21 (A/Texas/50/2012 (H3N2) )429 (352 to 523)485 (397 to 592)470 (382 to 577)
Day 0 (A/Switzerland/9715293/2013 (H3N2))65 (50 to 83)55 (43 to 71)60 (47 to 78)
Day 21 (A/Switzerland/9715293/2013 (H3N2))159 (128 to 198)187 (150 to 234)151 (122 to 188)
PrimaryGeometric Mean Ratio (GMR) Specific for the HA Receptor Binding Domains of Each of the Virus Strains Included in the NanoFlu as Measured by the HAI Assay.

The immunogenicity of Tri-NIV at 2 different doses, and the licensed comparator Fluzone HD (Sanofi Pasteur), in healthy older adults ≥ 60 years of age, based on hemagglutination inhibition (HAI) responses to vaccine-homologous influenza A and B strains, as recommended for the 2017 - 18 Northern hemisphere vaccine, at Day 21 post-dosing expressed as GMR.

Time frame:
Day 0 - Day 21 post dosing
Reported as:
Geometric mean · Ratio
Geometric Mean Ratio (GMR) Specific for the HA Receptor Binding Domains of Each of the Virus Strains Included in the NanoFlu as Measured by the HAI Assay.
RatioGroup A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21.
Day 21 (A/Michigan/45/2015 (H1N1))2.47 (2.05 to 2.98)3.86 (3.07 to 4.85)4.55 (3.60 to 5.75)
Day 21 (A/HongKong/4801/2014 (H3N2) )2.35 (1.94 to 2.84)3.49 (2.78 to 4.37)3.57 (2.87 to 4.45)
Day 21 (B/Brisbane/60/2008 (Victoria Lineage))1.30 (1.16 to 1.44)1.57 (1.39 to 1.78)2.56 (2.10 to 3.11)
Day 21 (A/California/07/2009 (H1N1) )2.20 (1.87 to 2.59)3.29 (2.67 to 4.05)3.94 (3.16 to 4.92)
Day 21 (A/Texas/50/2012 (H3N2) )2.17 (1.83 to 2.58)3.04 (2.48 to 3.72)2.40 (2.01 to 2.87)
Day 21 (A/Switzerland/9715293/2013 (H3N2))2.46 (2.04 to 2.95)3.38 (2.72 to 4.21)2.51 (2.08 to 3.02)
PrimarySeroconversion Rate (SCR) Specific for the HA Receptor Binding Domains of Each of the Virus Strains Included in the NanoFlu as Measured by the HAI Assay.

The immunogenicity of Tri-NIV at 2 different doses, and the licensed comparator Fluzone HD (Sanofi Pasteur), in healthy older adults ≥ 60 years of age, based on hemagglutination inhibition (HAI) responses to vaccine-homologous influenza A and B strains, as recommended for the 2017 - 18 Northern hemisphere vaccine, at Day 21 post-dosing expressed as SCRs.

Time frame:
Day 0 - Day 21 post dosing
Reported as:
Number · participants
Seroconversion Rate (SCR) Specific for the HA Receptor Binding Domains of Each of the Virus Strains Included in the NanoFlu as Measured by the HAI Assay.
participantsGroup A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21.
Day 21 (A/Michigan/45/2015 (H1N1))344954
Day 21 (A/HongKong/4801/2014 (H3N2) )243443
Day 21 (B/Brisbane/60/2008 (Victoria Lineage))51329
Day 21 (A/California/07/2009 (H1N1) )244553
Day 21 (A/Texas/50/2012 (H3N2) )213829
Day 21 (A/Switzerland/9715293/2013 (H3N2))284330
PrimaryNumber of Participants With Seroprotection Specific for the HA Receptor Binding Domains of Each of the Virus Strains Included in the NanoFlu as Measured by the HAI Assay.

The immunogenicity of Tri-NIV at 2 different doses, and the licensed comparator Fluzone HD (Sanofi Pasteur), in healthy older adults ≥ 60 years of age, based on hemagglutination inhibition (HAI) responses to vaccine-homologous influenza A and B strains, as recommended for the 2017 - 18 Northern hemisphere vaccine, at Day 21 post-dosing expressed as SPRs. Seroprotection rate (SPR) - defined as the number of subjects with an HAI titer ≥ 1:40.

Time frame:
Day 0 - Day 21 post dosing
Reported as:
Number · participants
Number of Participants With Seroprotection Specific for the HA Receptor Binding Domains of Each of the Virus Strains Included in the NanoFlu as Measured by the HAI Assay.
participantsGroup A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21.
Day 0 (A/Michigan/45/2015 (H1N1))656357
Day 21 (A/Michigan/45/2015 (H1N1))939698
Day 0 (A/HongKong/4801/2014 (H3N2) )514545
Day 21 (A/HongKong/4801/2014 (H3N2) )767989
Day 0 (B/Brisbane/60/2008 (Victoria Lineage))313019
Day 21 (B/Brisbane/60/2008 (Victoria Lineage))425357
Day 0 (A/California/07/2009 (H1N1) )807774
Day 21 (A/California/07/2009 (H1N1) )98102104
Day 0 (A/Texas/50/2012 (H3N2) )989698
Day 21 (A/Texas/50/2012 (H3N2) )109110108
Day 0 (A/Switzerland/9715293/2013 (H3N2))797173
Day 21 (A/Switzerland/9715293/2013 (H3N2))101103100
SecondaryGeometric Mean Titers (GMT) Specific for the HA Receptor Binding Domains of at Least 2 Historic A Virus Strains (One H1N1 and One H3N2) as Measured by the HAI Assay

The immunogenicity of Tri-NIV at 2 different doses and the licensed comparator Fluzone HD (Sanofi Pasteur) based on hemagglutination inhibition (HAI) responses to at least 2 historic and/or drifted A virus strains (one H1N1 and one H3N2) expressed as GMTs.

Time frame:
Day 0 - Day 21
Reported as:
Geometric mean · titers
Geometric Mean Titers (GMT) Specific for the HA Receptor Binding Domains of at Least 2 Historic A Virus Strains (One H1N1 and One H3N2) as Measured by the HAI Assay
titersGroup A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21.
A/Michigan/45/2015 (H1N1) : Day 069 (61 to 78)66 (59 to 74)65 (58 to 74)
A/Michigan/45/2015 (H1N1): Day 21146 (120 to 178)210 (171 to 258)171 (141 to 206)
A/HongKong/4801/2014 (H3N2) : Day 060 (53 to 69)58 (51 to 66)62 (53 to 74)
A/HongKong/4801/2014 (H3N2) : Day 21127 (103 to 157)159 (126 to 201)116 (91 to 147)
SecondaryGeometric Mean Ratio (GMR) Specific for the HA Receptor Binding Domains of at Least 2 Historic A Virus Strains (One H1N1 and One H3N2) as Measured by the HAI Assay

The immunogenicity of Tri-NIV at 2 different doses and the licensed comparator Fluzone HD (Sanofi Pasteur) based on hemagglutination inhibition (HAI) responses to at least 2 historic and/or drifted A virus strains (one H1N1 and one H3N2) expressed as GMRs.

Time frame:
Day 0 - Day 21
Reported as:
Geometric mean · Ratio
Geometric Mean Ratio (GMR) Specific for the HA Receptor Binding Domains of at Least 2 Historic A Virus Strains (One H1N1 and One H3N2) as Measured by the HAI Assay
RatioGroup A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21.
A/Michigan/45/2015 (H1N1) : Day 212.13 (1.83 to 2.48)3.17 (2.61 to 3.85)2.61 (2.21 to 3.09)
A/HongKong/4801/2014 (H3N2) : Day 212.10 (1.75 to 2.53)2.74 (2.22 to 3.38)1.85 (1.56 to 2.20)
SecondarySeroconversion Rate (SCR) Specific for the HA Receptor Binding Domains of at Least 2 Historic A Virus Strains (One H1N1 and One H3N2) as Measured by the HAI Assay

The immunogenicity of Tri-NIV at 2 different doses and the licensed comparator Fluzone HD (Sanofi Pasteur) based on hemagglutination inhibition (HAI) responses to at least 2 historic and/or drifted A virus strains (one H1N1 and one H3N2) expressed as SCRs.

Time frame:
Day 0 - Day 21
Reported as:
Number · participants
Seroconversion Rate (SCR) Specific for the HA Receptor Binding Domains of at Least 2 Historic A Virus Strains (One H1N1 and One H3N2) as Measured by the HAI Assay
participantsGroup A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21.
A/Michigan/45/2015 (H1N1): Day 2127 (17.0 to 34.0)45 (31.6 to 50.7)40 (27.7 to 46.5)
A/Michigan/45/2015 (H1N1) : Day 2129 (18.6 to 35.9)38 (25.7 to 44.2)25 (15.4 to 32.0)
SecondaryNumber of Participants With Seroprotection Specific for the HA Receptor Binding Domains of at Least 2 Historic A Virus Strains (One H1N1 and One H3N2) as Measured by the HAI Assay

The immunogenicity of Tri-NIV at 2 different doses and the licensed comparator Fluzone HD (Sanofi Pasteur) based on hemagglutination inhibition (HAI) responses to at least 2 historic and/or drifted A virus strains (one H1N1 and one H3N2) expressed as SPRs. Seroprotection rate (SPR) - defined as the percentage of subjects with an HAI titer ≥ 1:40.

Time frame:
Day 0 - Day 21
Reported as:
Number · percentage of participants
Number of Participants With Seroprotection Specific for the HA Receptor Binding Domains of at Least 2 Historic A Virus Strains (One H1N1 and One H3N2) as Measured by the HAI Assay
percentage of participantsGroup A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21.
A/Michigan/45/2015 (H1N1) : Day 099.1 (95.0 to 100.0)98.2 (93.6 to 99.8)97.2 (92.2 to 99.4)
A/Michigan/45/2015 (H1N1) : Day 21100.0 (96.7 to 100.0)100 (96.7 to 100.0)99.1 (95.0 to 100.0)
A/HongKong/4801/2014 (H3N2) : Day 097.2 (92.2 to 99.4)96.4 (91.0 to 99.0)90.8 (83.8 to 95.5)
A/HongKong/4801/2014 (H3N2) : Day 21100.0 (96.7 to 100.0)98.2 (93.6 to 99.8)94.5 (88.4 to 98.0)
SecondaryGeometric Mean Titers (GMT) for Neutralizing Antibody Titers Specific for the Virus Strains Included in NanoFlu and the Fluzone HD Comparator, as Well as Selected Historical A Strains, as Measured by a Microneutralization Assay.

The immunogenicity of Tri-NIV at 2 different doses, and the licensed comparator Fluzone HD (Sanofi Pasteur), based on microneutralization (MN) responses to vaccine-homologous and historic and/or drifted influenza A strains, and the vaccine-homologous B/Victoria lineage strain, at Day 21 post-dosing expressed as GMTs.

Time frame:
Day 0 - Day 21 post dosing
Reported as:
Geometric mean · titers
Geometric Mean Titers (GMT) for Neutralizing Antibody Titers Specific for the Virus Strains Included in NanoFlu and the Fluzone HD Comparator, as Well as Selected Historical A Strains, as Measured by a Microneutralization Assay.
titersGroup A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21.
Day 0 (A/Switzerland/9715293/2013 (H3N2))1696 (1292 to 2227)1258 (954 to 1658)1400 (1046 to 1873)
Day 21 (A/Switzerland/9715293/2013 (H3N2))4419 (3391 to 5758)5223 (3997 to 6824)3011 (2268 to 3997)
Day 0 (A/Texas/50/2012 (H3N2))3660 (2803 to 4778)2768 (2142 to 3577)3307 (2484 to 4402)
Day 21 (A/Texas/50/2012 (H3N2))9204 (7165 to 11822)10495 (8213 to 13410)8383 (6409 to 10964)
Day 0 (A/Singapore/INFIMH-16-0019/2016 (H3N2)587 (461 to 748)437 (349 to 547)489 (367 to 651)
Day 21 (A/Singapore/INFIMH-16-0019/2016 (H3N2)1469 (1113 to 1940)1640 (1254 to 2146)1905 (1434 to 2531)
Day 0 (A/Michigan/45/2015 (H1N1))411 (327 to 516)342 (269 to 436)334 (259 to 432)
Day 21 (A/Michigan/45/2015 (H1N1))1414 (1070 to 1868)2005 (1485 to 2708)1741 (1313 to 2309)
Day 0 (A/HongKong/4801/2014 (H3N2) )1239 (957 to 1605)891 (698 to 1137)1081 (816 to 1433)
Day 21 (A/HongKong/4801/2014 (H3N2) )3359 (2577 to 4378)3791 (2906 to 4944)4455 (3426 to 5793)
Day 0 (B/Brisbane/60/2008 (Victoria Lineage))167 (129 to 216)174 (137 to 220)154 (124 to 193)
Day 21 (B/Brisbane/60/2008 (Victoria Lineage))287 (228 to 361)354 (285 to 439)425 (341 to 529)
SecondaryGeometric Mean Ratio (GMR) for Neutralizing Antibody Titers Specific for the Virus Strains Included in NanoFlu and the Fluzone HD Comparator, as Well as Selected Historical A Strains, as Measured by a Microneutralization Assay.

The immunogenicity of Tri-NIV at 2 different doses, and the licensed comparator Fluzone HD (Sanofi Pasteur), based on microneutralization (MN) responses to vaccine-homologous and historic and/or drifted influenza A strains, and the vaccine-homologous B/Victoria lineage strain, at Day 21 post-dosing expressed as GMRs.

Time frame:
Day 0 - Day 21
Reported as:
Geometric mean · Ratio
Geometric Mean Ratio (GMR) for Neutralizing Antibody Titers Specific for the Virus Strains Included in NanoFlu and the Fluzone HD Comparator, as Well as Selected Historical A Strains, as Measured by a Microneutralization Assay.
RatioGroup A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21.
Day 21 (A/Switzerland/9715293/2013 (H3N2))2.61 (2.13 to 3.19)4.15 (3.25 to 5.31)2.15 (1.82 to 2.55)
Day 21 (A/Texas/50/2012 (H3N2))2.51 (2.04 to 3.10)3.79 (3.05 to 4.72)2.53 (2.09 to 3.07)
Day 21 (A/Singapore/INFIMH-16-0019/2016 (H3N2))2.50 (1.99 to 3.15)3.76 (2.98 to 4.74)3.90 (3.09 to 4.92)
Day 21: A/Michigan/45/2015 (H1N1)3.44 (2.74 to 4.33)5.86 (4.45 to 7.72)5.21 (3.94 to 6.89)
Day 21: A/HongKong/4801/2014 (H3N2)2.71 (2.20 to 3.33)4.25 (3.34 to 5.42)4.12 (3.26 to 5.20)
Day 21: B/Brisbane/60/2008 (Victoria Lineage)1.72 (1.48 to 2.00)2.03 (1.70 to 2.43)2.75 (2.19 to 3.47)
SecondarySeroconversion Rate (SCR) for Neutralizing Antibody Titers Specific for the Virus Strains Included in NanoFlu and the Fluzone HD Comparator, as Well as Selected Historical A Strains, as Measured by a Microneutralization Assay.

The immunogenicity of Tri-NIV at 2 different doses, and the licensed comparator Fluzone HD (Sanofi Pasteur), based on microneutralization (MN) responses to vaccine-homologous and historic and/or drifted influenza A strains, and the vaccine-homologous B/Victoria lineage strain, at Day 21 post-dosing expressed as SPRs.

Time frame:
Day 0 - Day 21
Reported as:
Number · participants
Seroconversion Rate (SCR) for Neutralizing Antibody Titers Specific for the Virus Strains Included in NanoFlu and the Fluzone HD Comparator, as Well as Selected Historical A Strains, as Measured by a Microneutralization Assay.
participantsGroup A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21.
Day 21 (A/Switzerland/9715293/2013 (H3N2))22 (13.1 to 29.0)45 (31.6 to 50.7)20 (11.6 to 26.9)
Day 21 (A/Texas/50/2012 (H3N2))26 (16.2 to 33.0)47 (33.3 to 52.5)28 (17.8 to 34.9)
Day 21 (A/Singapore/INFIMH-16-0019/2016 (H3N2)27 (17.0 to 34.0)38 (25.7 to 44.2)43 (30.2 to 49.3)
Day 21: A/Michigan/45/2015 (H1N1)33 (21.8 to 39.8)53 (38.6 to 57.9)50 (36.3 to 55.7)
Day 21: A/HongKong/4801/2014 (H3N2)28 (17.8 to 34.9)43 (29.9 to 48.9)48 (34.5 to 53.9)
Day 21: B/Brisbane/60/2008 (Victoria Lineage)13 (6.5 to 19.5)18 (10.0 to 24.6)23 (13.9 to 30.0)

Adverse events

Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 210/109 (0%)7/109 (6.4%)32/109 (29.4%)
Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 210/111 (0%)11/111 (9.9%)27/111 (24.3%)
Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21.0/110 (0%)8/110 (7.3%)28/110 (25.5%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventGroup A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21.
CEREBROVASCULAR ACCIDENTNervous system disorders0/1092/1110/110
ATRIAL FIBRILLATIONCardiac disorders1/1090/1111/110
CHEST DISCOMFORTGeneral disorders1/1090/1110/110
PELVIC ABSCESSInfections and infestations1/1090/1110/110
SEROMAInjury, poisoning and procedural complications1/1090/1110/110
PROSTATE CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1090/1110/110
SYNCOPENervous system disorders1/1090/1110/110
NEPHROLITHIASISRenal and urinary disorders1/1090/1110/110
PYREXIAGeneral disorders0/1090/1111/110
BETA HAEMOLYTIC STREPTOCOCCAL INFECTIONInfections and infestations0/1090/1111/110
Most frequent other events
Most frequent other events
EventGroup A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21.
BRONCHITISInfections and infestations11/1099/1116/110
BLOOD PRESSURE SYSTOLIC INCREASEDInvestigations11/1094/1118/110
SINUSITISInfections and infestations4/1095/1117/110
HEADACHENervous system disorders2/1097/1111/110
HYPERTENSIONVascular disorders4/1092/1116/110

Baseline characteristics

330 participants were randomized to 1 of 3 treatment groups based on age, gender, and history of receipt of the 2016 - 17 influenza vaccine.

Age, Customized
Age, Customized(Participants)Group A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21.Total
60 to < 75 years909190271
≥ 75 years19202059
Sex: Female, Male
Sex: Female, Male(Participants)Group A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21.Total
Female586057175
Male515153155
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21.Total
Hispanic or Latino1113
Not Hispanic or Latino108110109327
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21.Total
American Indian or Alaska Native1001
Asian0011
Native Hawaiian or Other Pacific Islander0000
Black or African American1713939
White919899288
More than one race0011
Unknown or Not Reported0000
History of Prior Flu Vaccinations
History of Prior Flu Vaccinations(participants)Group A- Participants Received Low Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group B- Participants Received High Dose Tri-NIV Vaccine at Day 0 and Received Fluzone HD at Day 21Group C - Participants Received Fluzone HD at Day 0 and Received Dose of Placebo at Day 21.Total
Receipt of 2016 - 17 Flu Vaccine959493282
Receipt of Flu Vaccine in Past 3 Years102101102305
08

Study locations

3 sites
  • Research Site US108
    Raleigh, North Carolina 27609, United States
  • Research Site US106
    Rocky Mount, North Carolina 27804, United States
  • Research Site US132
    Statesville, North Carolina 28625, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Mar 2018, 5 months.

Results were first posted in Dec 2022, 4 years 9 months after primary completion. A results delay was requested in Aug 2019.

Of 41 industry-sponsored phase 1/2 interventional studies under Influenza, Human, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 5 months is below that.

Counting every sponsor, half of 43 studies reached it within 12 months; a quarter within 7 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2017
First posted
Sep 26, 2017
StartActual
Sep 18, 2017
Primary completionActual
Mar 14, 2018
CompletionActual
Oct 29, 2018
Results delay requested
Aug 20, 2019
Results first posted
Dec 21, 2022
Last update
Dec 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03293498
Lead sponsor
Novavax
Responsible party
Sponsor
First posted
Sep 26, 2017
Start date
Sep 18, 2017
Primary completion
Mar 14, 2018
Completion
Oct 29, 2018
Results posted
Dec 21, 2022
Last update
Dec 21, 2022

Study contacts

Clinical Development
study director · Novavax

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion